Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
Portfolio Pulse from Vuk Zdinjak
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) has received positive feedback from the FDA for its drug ANEB-001, used for acute cannabinoid intoxication (ACI). The FDA suggests that a single well-controlled study of ANEB-001 could potentially support a new drug application. Anebulo has also completed dosing in an open-label part C extension of its phase 2 clinical trial to evaluate the safety and efficacy of ANEB-001. Full safety, pharmacokinetic, and pharmacodynamic data from the study are expected in Q4 2023.
August 21, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anebulo Pharmaceuticals has received positive feedback from the FDA for its drug ANEB-001. This could potentially lead to a new drug application. Full data from the phase 2 clinical trial is expected in Q4 2023.
The positive feedback from the FDA is a significant step towards the approval of ANEB-001. This could potentially lead to a new drug application, which would be a major milestone for Anebulo. The completion of the phase 2 clinical trial and the expected data in Q4 2023 could provide further validation for the drug and potentially boost the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100